These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 17292840)

  • 21. Protein promiscuity: drug resistance and native functions--HIV-1 case.
    Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
    J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: possible contributions to drug resistance and a potential new target site for drugs.
    Perryman AL; Lin JH; McCammon JA
    Protein Sci; 2004 Apr; 13(4):1108-23. PubMed ID: 15044738
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir.
    Kagan RM; Shenderovich MD; Heseltine PN; Ramnarayan K
    Protein Sci; 2005 Jul; 14(7):1870-8. PubMed ID: 15937277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug Resistance Mechanism of L10F, L10F/N88S and L90M mutations in CRF01_AE HIV-1 protease: Molecular dynamics simulations and binding free energy calculations.
    Vasavi CS; Tamizhselvi R; Munusami P
    J Mol Graph Model; 2017 Aug; 75():390-402. PubMed ID: 28645089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insights into the mechanism of drug resistance: X-ray structure analysis of multi-drug resistant HIV-1 protease ritonavir complex.
    Liu Z; Yedidi RS; Wang Y; Dewdney TG; Reiter SJ; Brunzelle JS; Kovari IA; Kovari LC
    Biochem Biophys Res Commun; 2013 Feb; 431(2):232-8. PubMed ID: 23313846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Computational simulations of HIV-1 proteases--multi-drug resistance due to nonactive site mutation L90M.
    Ode H; Neya S; Hata M; Sugiura W; Hoshino T
    J Am Chem Soc; 2006 Jun; 128(24):7887-95. PubMed ID: 16771502
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combating susceptibility to drug resistance: lessons from HIV-1 protease.
    King NM; Prabu-Jeyabalan M; Nalivaika EA; Schiffer CA
    Chem Biol; 2004 Oct; 11(10):1333-8. PubMed ID: 15489160
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural basis for coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease.
    Prabu-Jeyabalan M; Nalivaika EA; King NM; Schiffer CA
    J Virol; 2004 Nov; 78(22):12446-54. PubMed ID: 15507631
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relation between flexibility and positively selected HIV-1 protease mutants against inhibitors.
    Braz AS; Tufanetto P; Perahia D; Scott LP
    Proteins; 2012 Dec; 80(12):2680-91. PubMed ID: 22821809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hydrophobic core flexibility modulates enzyme activity in HIV-1 protease.
    Mittal S; Cai Y; Nalam MN; Bolon DN; Schiffer CA
    J Am Chem Soc; 2012 Mar; 134(9):4163-8. PubMed ID: 22295904
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A molecular dynamics study comparing a wild-type with a multiple drug resistant HIV protease: differences in flap and aspartate 25 cavity dimensions.
    Seibold SA; Cukier RI
    Proteins; 2007 Nov; 69(3):551-65. PubMed ID: 17623840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-active site mutations in the HIV protease: Diminished drug binding affinity is achieved through modulating the hydrophobic sliding mechanism.
    Sherry D; Pandian R; Sayed Y
    Int J Biol Macromol; 2022 Sep; 217():27-41. PubMed ID: 35817239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A hierarchical model of HIV-1 protease drug resistance.
    Goodsell DS
    Appl Bioinformatics; 2002; 1(1):3-12. PubMed ID: 15130852
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular dynamics simulations applied to the study of subtypes of HIV-1 protease common to Brazil, Africa, and Asia.
    Batista PR; Wilter A; Durham EH; Pascutti PG
    Cell Biochem Biophys; 2006; 44(3):395-404. PubMed ID: 16679526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insights into drug resistance of mutations D30N and I50V to HIV-1 protease inhibitor TMC-114: free energy calculation and molecular dynamic simulation.
    Chen J; Zhang S; Liu X; Zhang Q
    J Mol Model; 2010 Mar; 16(3):459-68. PubMed ID: 19629548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of the activity of HIV-1 protease through antibody binding and mutations probed by molecular dynamics simulations.
    Badaya A; Sasidhar YU
    Sci Rep; 2020 Mar; 10(1):5501. PubMed ID: 32218488
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insights into a mutation-assisted lateral drug escape mechanism from the HIV-1 protease active site.
    Sadiq SK; Wan S; Coveney PV
    Biochemistry; 2007 Dec; 46(51):14865-77. PubMed ID: 18052195
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.
    Kozísek M; Bray J; Rezácová P; Sasková K; Brynda J; Pokorná J; Mammano F; Rulísek L; Konvalinka J
    J Mol Biol; 2007 Dec; 374(4):1005-16. PubMed ID: 17977555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanism of drug resistance due to N88S in CRF01_AE HIV-1 protease, analyzed by molecular dynamics simulations.
    Ode H; Matsuyama S; Hata M; Hoshino T; Kakizawa J; Sugiura W
    J Med Chem; 2007 Apr; 50(8):1768-77. PubMed ID: 17367119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.
    Vega S; Kang LW; Velazquez-Campoy A; Kiso Y; Amzel LM; Freire E
    Proteins; 2004 May; 55(3):594-602. PubMed ID: 15103623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.